MedTrace Logo

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

NCT05769751 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 865

Last updated 2023-08-16

No results posted yet for this study

Summary

This is a multicenter, non-interventional, retrospective, real-world study that enrolled patients diagnosed with HER2-positive unresectable or metastatic breast cancer. This study will be conducted to understand the treatment pattern and sequencing of therapies, survival outcomes, and associated burden of toxicities with line of treatment in the real world.

Conditions

Interventions

OTHER

Electronic medical record and hospital information system or other available resources

This is a non-interventional study. No study medication will be provided to the participants.

Sponsors & Collaborators

Principal Investigators

  • Clinical Team Leader · Daiichi Sankyo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2023-07-25
Completion
2023-07-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05769751 on ClinicalTrials.gov